Anakinra at the heart of the matter in MIS-C

Article Rheumatology

Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity

Andrea Taddio et al.

Summary: The study aimed to determine the best treatment option for multisystem inflammatory syndrome in children (MIS-C) and analyze the role of anakinra. The results showed that early treatment with anakinra can reduce the probability of developing persistent heart disease at the end of follow-up.

RHEUMATOLOGY (2023)

添加到收藏夹

Article Rheumatology

Who Would Have Predicted Multisystem Inflammatory Syndrome in Children?

Daniel D. Reiff et al.

Summary: This review provides an in-depth analysis of multisystem inflammatory disease in children (MIS-C) following COVID-19. It discusses the clinical findings, pathophysiology, imaging and laboratory studies, treatment algorithms, and disease outcomes. MIS-C can be challenging to diagnose due to its non-specific presentation, but accurate diagnosis can be achieved through common laboratory features, imaging findings, and historical clues, enabling appropriate treatment with therapies such as IVIG. Aggressive treatment leads to good outcomes, and longitudinal studies shed light on long-term cardiac sequelae and recovery.

CURRENT RHEUMATOLOGY REPORTS (2022)

添加到收藏夹

Article Rheumatology

American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 3

Lauren A. Henderson et al.

Summary: This study provides guidance on the management of Multisystem Inflammatory Syndrome in Children (MIS-C) and hyperinflammation during COVID-19. The guidance was developed through expert consensus and includes 41 guidance statements and flow diagrams for the diagnosis and initial treatment of MIS-C.

ARTHRITIS & RHEUMATOLOGY (2022)

添加到收藏夹

Article Virology

Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children

Daniel D. Reiff et al.

Viruses-Basel (2022)

添加到收藏夹

Article Medicine, General & Internal

Postdischarge Glucocorticoid Use and Clinical Outcomes of Multisystem Inflammatory Syndrome in Children

Mary Beth F. Son et al.

Summary: This multicenter cohort study evaluated the clinical characteristics and outcomes of postdischarge glucocorticoid treatment in children with multisystem inflammatory syndrome in children (MIS-C). The study found that many patients with MIS-C continued glucocorticoid treatment after discharge, but clinical outcomes were similar in patients prescribed shorter courses. Outpatient weight gain was common, but readmission for cardiovascular dysfunction was infrequent. The findings suggest the need for optimizing postdischarge glucocorticoid regimens for patients with MIS-C.

JAMA NETWORK OPEN (2022)

添加到收藏夹

Article Pediatrics

Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19

Sengul Caglayan et al.

Summary: This study aimed to evaluate the efficacy and safety of anakinra treatment in children with refractory multisystemic inflammatory syndrome (MIS-C). The results showed that anakinra was associated with clinical improvements and was considered safe for most patients with refractory MIS-C.

FRONTIERS IN PEDIATRICS (2022)

添加到收藏夹

Article Pediatrics

6-month multidisciplinary follow-up and outcomes of patients with paediatric inflammatory multisystem syndrome (PIMS-TS) at a UK tertiary paediatric hospital: a retrospective cohort study

Justin Penner et al.

Summary: This study on the 6-month outcomes of paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 infection found that while most patients had resolved organ-specific sequelae by 6 months, long-term physical re-conditioning and mental health support were still needed for some, with persisting exercise tolerance issues and emotional difficulties identified.

LANCET CHILD & ADOLESCENT HEALTH (2021)

添加到收藏夹

Article Rheumatology